Oct 09,2023

Continuous Glucose Monitoring Market Size & Share Surpass USD 2 billion by 2028 – Exclusive Report by Transparency Market Research

The continuous glucose monitoring market revenues are expected to rise at a CAGR of 9.5% from 2021 to 2028, and projected to reach US$ 2 billion by 2028, according to the research publisher. Increasing demand for smart wearables and increasing incidence of chronic diseases are expected to drive the market in the coming years.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2023

Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Ascensia Diabetes Care and Senseonics Holdings have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. A sample of the new advertising assets can be found in the press release article link. Eversense E3 is the longest lasting CGM available, with 6-month sensor wear duration and two sensor insertion and removal procedures per year.

View Analyst & Ambassador Comments
Go to original news
Oct 11,2023 TOP STORY

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Better Therapeutics announced new findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D). The analysis reveals that adjunctive use of AspyreRx with standard of care, including GLP-1 receptor agonists (GLP-1), leads to a substantially greater clinical improvement compared to control participants who did not incorporate AspyreRx into their regimen. The subgroup analysis, involving approximately 160 participants on GLP-1s randomized to the active and control arm of the study, exhibited an average reduction in HbA1c of 0.7% at 90 days, between the two groups. This exceeds the results of the entire BT-001 pivotal trial population, where AspyreRx outperformed the standard of care control arm by 0.4%. The new subgroup analysis data may be particularly relevant in the context of recent draft guidance from the FDA, titled 'Regulatory Considerations for Prescription Drug Use-Related Software,' released in September, which provides clarity about the agency’s views and intent to consider the combined effectiveness of pharmaceuticals and digital therapeutic solutions when making drug labeling decisions.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

InsideTracker & Nutrisense CGM Bundle: Take Control of Your Metabolic Health

InsideTracker and Nutrisense partnered to offer a budled service experience for Nutrisense users. With access to CGMs, expert nutritionist support, and the Nutrisense app, users can spot patterns and trends in their glucose data by observing real-time glucose responses to food, stress, exercise, sleeping habits, and much more. In the bundle, subscribers will get access InsideTracker's Ultimate Plan including comprehensive blood testing, analysis, and wellness plan, and InnerAge 2.0 calculation for biological age based on personal blood biomarker data. At the same time, Nutrisense will be offering 2 CGM sensors, 1:1 nutritionist support and 1 month subscription in the Nutrisense app in the bundle package.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023 TOP STORY

Dario Signs National Preferred Partner Agreement with a Top Five National Employee Benefits Consulting Firm

DarioHealth announced a new strategic partnership with a top five national employee benefits consulting firm. Through the preferred partnership agreement, Dario becomes the digital chronic condition management option for the Firm's clients looking to implement a solution to address diabetes, pre-diabetes, hypertension, musculoskeletal and behavioral health needs.

COLLABORATION PARTNERSHIP

#institution

#dtx

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023 TOP STORY

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Dexcom announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. The Dexcom G7 CGM System will be available to purchase in pharmacies across Canada as of Tuesday, October 10, 2023. Dexcom G7 offers real-time glucose readings sent automatically to a compatible display device, and a predictive alert that alerts users up to 20 minutes in advance of severe hypoglycemia for prevention.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023

Lupin unveils digital diabetes support app

Mumbai-based global pharmaceutical company Lupin has launched a mobile-based patient support programme for persons with diabetes. The digital diabetes management programme called Humrahi (which translates to "companion" in Urdu) offers doctor-guided comprehensive support, including personalised diet counselling, medication assistance, and tailored lifestyle modifications. It also features a guide for precise insulin injection. Humrahi is now available on both iOS and Android devices and online via its website.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Journeys Metabolic unveils the first enterprise intervention platform for improving metabolic health at scale

Journeys Metabolic, an enterprise intervention platform that helps value-based organizations improve clinical and financial outcomes for metabolic disease, announced today the availability of its novel digital solution. The Journeys Metabolic HI-TRUST, EHR-interoperable platform enables clinical and financial decision-makers, including care management teams, to standardize metabolic care for their population health initiatives via an automated provider workflow engaging qualified, targeted patient populations. The core clinical component of the platform is a 4-month, physician-developed, digital program that drives long-term behavior modification to support the reversal and prevention of metabolic disease initiatives for patients with type 2 diabetes, NAFLD, metabolic syndrome, and obesity. The program will leverage AI-driven behavioral archetyping and diagnostic profiling to provide a personalized, precision-guided nutritional experience.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news
Oct 02,2023

Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5

Insulet Corporation announced its schedule of events and presentations at EASD 2023, taking place today through October 6 in Hamburg, Germany, and online. Insulet will sponsor a symposium, “Real-World Experience with Omnipod 5: Prioritizing Users’ Needs with Tubeless Innovation.” Dr. Ly will be joined by Dr. Torben Biester, a pediatric diabetes specialist from Germany, who will discuss the impact diabetes technology can have on quality of life for people with diabetes, considering usability and treatment satisfaction of Pod therapy. The symposium will take place on Monday, October 2 from 4:00 – 5:00 p.m. CEST in Sydney Hall.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 02,2023 TOP STORY

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

Dexcom announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany. New results from the COMISAIR seven-year study, the longest prospective real-world CGM study ever conducted, show significant and continued reduction of HbA1c with the use of real-time CGM by people with Type 1 diabetes. Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years. The COMISAIR study also shows further substantial reduction in HbA1c when real-time CGM is connected to an automated insulin delivery system, specifically Tandem Control IQ. Dexcom announced the Dexcom G7 CGM system will begin launching with the Tandem t:slim X2 insulin pump before the end of the year in the U.S. and multiple markets across Europe and Asia-Pacific. This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES